Loading
EIK1004 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.
PARP1-selective inhibitor, also called IMP1707. The sponsor describes CNS penetration as a development feature. The linked registry records distinguish recruiting, closed, and discontinued studies; those states do not establish comparative efficacy or approval.
PARP1-selective inhibitor, also called IMP1707. The sponsor describes CNS penetration as a development feature. Connects to PARP.
1.EIK1004 slips into a pocket on PARP.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"EIK1004" OR ABSTRACT:"EIK1004" OR TITLE:"IMP1707" OR ABSTRACT:"IMP1707") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EIK1004, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/